• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

NCCS Starburst 250px

Health Care Roundup: Drug Pricing Plan, 2019 Premium Increases, Short-Term Plans, Medicare Mulls Covering Gene Therapies, and More

May 18, 2018/in Cancer News, Cancer Policy Blog, NCCS News Access to Care, Affordable Care Act, Drug Pricing, Financial Toxicity, Health Care Coverage, Health Equity NCCS News /by actualize
In order to bring you the latest cancer-related health care policy and news, we at NCCS are combining our ACA Updates and What Caught Our Eye (WCOE) content into a weekly email and blog post. We aim to make this a concise, one-stop summary of what you need to know as we continue working together to make cancer care better for everyone.

Your feedback is always welcome to make our content more useful to you. Please send comments to feedback@canceradvocacy.org.

Subscribe to our email list and receive these updates in your email box each week »


HEALTH CARE HIGHLIGHTS

Trump Administration Promotes a Drug Pricing Plan

On Friday, May 11, 2018, President Trump announced a drug pricing blueprint to address prescription drug prices. Initial media coverage of the plan suggested that the blueprint failed to honor the President’s campaign commitment to negotiation of drug prices. Overall, the press and policymaker reaction to the plan was muted, with some suggesting that the plan would have limited impact. Although details of the plan are still unclear, certain elements of the plan may have an impact on how cancer patients receive and pay for their prescription drugs. There may be changes in the coverage and payment for both intravenous, physician-administered cancer drugs and oral, self-administered cancer therapies. The public has 60 days to comment on the drug pricing plan through the “Request for Information” released by the Trump Administration. NCCS will evaluate the direct patient impact of the plan provisions that relate to coverage and payment for cancer drugs and will outline the issues of concern to cancer patients.

Insurance Premium Increases for 2019, the Causes, and Efforts to Lower Them

Insurers have begun to project next year’s premiums for plans offered through the Affordable Care Act (ACA) marketplaces. The premiums that have been announced to date for 2019 are significant increases over premiums in 2018. Insurance companies signaled that adjustments to the premiums are possible if they receive relief from the costs associated with insuring expensive patients. Members of Congress are blaming each other for the premium increases. Congressional Democrats contend that the actions of the Trump Administration to undermine the ACA enrollment process and to advance short-term, limited-duration plans will further undermine the ACA marketplaces. The Trump Administration and some Congressional Republicans maintain that the ACA is fundamentally flawed and that repeal is still necessary. The Hill has reported that rate increases have reignited the “Obamacare war.” In fact, Senator Lindsay Graham is reportedly working on a “new” Obamacare repeal bill.

Short-Term Plans: Enrollment will be Significant and Negative Effects on Marketplace will be Substantial

The Trump Administration’s proposed expansion of short-term plans will reportedly be finalized by June 2018. These plans, sometimes called “skinny” or even “junk” plans, will not be required to meet ACA standards for benefits, cost-sharing, guaranteed issue, and pre-existing condition protections. The Administration has touted these plans as an affordable insurance option for healthy adults and has suggested that uptake of the plans will be slow and the impact on the ACA health insurance marketplaces will be modest.

This week, the Actuary of the Centers for Medicare & Medicaid Services (CMS), who is independent from the CMS leadership,  projected that 1.8 million Americans would elect short-term coverage, with 800,000 coming from the ACA marketplace. This projection means that almost 2 million Americans will have only short-term coverage of limited scope and significant cost-sharing burden and that the diversion of hundreds of thousands from the marketplace will destabilize the ACA marketplace. For cancer patients who rely on ACA coverage, premiums will increase, potentially substantially, if they are not eligible for premium subsidies. The expansion of short-term plans will also cost the federal government $38.7 billion over ten years with increased expenditures for premium subsidies, the CMS Actuary reported.

 


CHART OF THE WEEK


A Kaiser Family Foundation report entitled, “Implications of the ACA Medicaid Expansion: A Look at the Data and Evidence,” reported that “Medicaid expansion states experienced significant coverage gains and reductions in uninsured rates compared to non-expansion states for the low-income population broadly.”


IMPORTANT READS

Healthy America, a big new plan to combine Medicaid and Obamacare, explained

Via Vox.com

The Urban Institute, a think tank in Washington, DC, has acknowledged the deep divide about the ACA and the renewed push to repeal the ACA. They have proposed an alternative that protects employer-based insurance and Medicare and creates a new system for individual and families seeking health insurance coverage. Premiums in the system would be income-based and premium subsidies would be available for those who need them. The plan would also impose limits on provider payments and other cost controls would be implemented to control premium costs. The Urban Institute plan includes a chart that compares a wide range of health care reform proposals, identifying the strengths and weaknesses of each.

More men with low-risk prostate cancer are forgoing aggressive treatment

Via Washington Post

In a study published in the Journal of the American Medical Association (JAMA), researchers reported that men with low-risk prostate cancer are increasingly choosing active surveillance of their disease instead of surgery and radiation. The study, which included more than 125,000 men with prostate cancer treated between 2005 and 2015, found a major shift in treatment decisions over that decade. In 2005, only 27 percent of men under age 65 chose watchful waiting instead of active treatment. By 2015, that proportion had grown to 72 percent. Cancer care experts are applauding the shift in treatment choices, which spares men the serious side effects of treatment and results in comparable outcomes.

CMS considers paying all Medicare providers for cancer gene therapies

Via Modern Healthcare

The Centers for Medicare & Medicaid Services (CMS) has initiated a review of how and under what terms the Medicare program will cover the recently approved CAR T-cell therapies. These therapies have provided significant benefits to certain leukemia and lymphoma patients.  Some patients experience serious side effects from the treatments.  Public comment on the review is accepted until June 15, 2018.  A public meeting will be held on August 22, 2018.  The final decision is due on February 16, 2019.


Tags: aca update, Advocacy, affordable care act, drug pricing, financial issues, junk insurance, Medicaid, Medicare, short-term health plans, What Caught Our Eye
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2017/01/NCCS-Starburst-250px.png 250 250 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2018-05-18 13:48:582018-05-18 13:48:58Health Care Roundup: Drug Pricing Plan, 2019 Premium Increases, Short-Term Plans, Medicare Mulls Covering Gene Therapies, and More
You might also like
NCCS Policy Comments HHS bldg NCCS Letter to HHS Highlights “Deep Reservations” Concerning Massachusetts 1115 Waiver
FacebookProfile3 NCCS applauds establishment of cancer treatment planning and care coordination reimbursement codes
FacebookProfile3 What effects the health care law has had and what’s to come
NCCS Starburst 250px What Caught Our Eye: Multiple Proposals Continue to Weaken ACA Patient Protections; Breast Cancer Cost Survey; Editing Genes to Treat Cancer
20years Dr. Julia Rowland Discusses the Importance of Psychosocial Care: Engagement and Dialogue
Dome Thumbnail starburst Cancer Leadership Council Comments on Essential Health Benefits
NCCS Starburst Thumbnail Department of Health and Human Services Releases Proposed Rules for Affordable Care Act, NCCS to Analyze
NCCS Starburst Thumbnail WCOE: Childhood Survivor Study on Cost, Dr. Gawande talks Care Quality, Lilly’s Tribute to Ellen, Smita Bhatia in Cure Magazine

Latest News

Coronavirus feat

COVID-19 Vaccines and Cancer: A Conversation with Cancer Expert Otis Brawley, MD

March 1, 2021
The National Coalition for Cancer Survivorship (NCCS) hosted a conversation on February…
Read more
https://canceradvocacy.org/wp-content/uploads/2020/03/Coronavirus-feat.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-01 11:49:192021-03-02 16:15:47COVID-19 Vaccines and Cancer: A Conversation with Cancer Expert Otis Brawley, MD
Canceradvocacy org default image

National Quality Forum Names NCCS CEO Shelley Fuld Nasso to 2021 Leadership Consortium Roster

February 24, 2021
NOTE: This press release was originally published on the National Quality Forum (NQF)…
Read more
https://canceradvocacy.org/wp-content/uploads/2019/10/Canceradvocacy-org-default-image.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-02-24 21:01:392021-02-24 21:01:39National Quality Forum Names NCCS CEO Shelley Fuld Nasso to 2021 Leadership Consortium Roster
HHS Humphrey bldg 1200

NCCS and Other Cancer Groups Urge HHS to Keep Six Protected Classes in Medicare Part D Drug Plans

February 19, 2021
The National Coalition for Cancer Survivorship (NCCS) joined with the Cancer Leadership…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-02-19 15:06:392021-02-24 19:29:10NCCS and Other Cancer Groups Urge HHS to Keep Six Protected Classes in Medicare Part D Drug Plans

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

Cancer Policy News Roundup: Proposed Cuts to CHIP, Association Health Plans... NCCS Starburst 250px NCCS Policy Comments Capitol NCCS Joins Cancer Leadership Council to Oppose Right to Try Legislation in the...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute